Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial
RCT (n=6,128) reports febuxostat is non-inferior to allopurinol therapy with respect to composite of hospitalisation for non-fatal myocardial infarction or biomarker-positive acute coronary syndrome, non-fatal stroke or cardiovascular death.
Source:
The Lancet
SPS commentary:
Authors’ of a related commentary state that despite febuxostat filling an important therapeutic gap, being particularly useful in patients who are refractory or intolerant to allopurinol and requiring no dose limitation in chronic kidney disease of stages 1–3; it was not readily approved because pivotal trials had shown a nominal increase in cardiovascular deaths. Authors’ subsequently highlight the positive safety profile of febuxostat demonstrated in this trial, which showed long-term use of febuxostat is not associated with an increased risk of death or serious adverse events compared with allopurinol.